Literature DB >> 2613331

Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis.

W Kern1, K Linzmeier, E Kurrle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2613331     DOI： 10.1007/bf01645556

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  11 in total

Review 1.  Modulation of the host flora.

Authors:  R van Furth; H F Guiot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-01       Impact factor: 3.267

2.  Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients.

Authors:  M Venditti; P Baiocchi; C Santini; C Brandimarte; P Serra; G Gentile; C Girmenia; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

3.  Streptococcal sepsis in bone marrow transplant patients.

Authors:  J Henslee; B Bostrom; D Weisdorf; N Ramsay; P McGlave; J Kersey
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

4.  Sepsis in febrile neutropenic children with cancer.

Authors:  J Langley; R Gold
Journal:  Pediatr Infect Dis J       Date:  1988-01       Impact factor: 2.129

5.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors:  J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

6.  Viridans streptococci septicemia in cancer patients: a clinical study.

Authors:  F Menichetti; A Del Favero; R Guerciolini; M Tonato; R F Frongillo; F Roila; S Pauluzzi
Journal:  Eur J Epidemiol       Date:  1987-09       Impact factor: 8.082

7.  High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.

Authors:  W Kern; E Kurrle; E Vanek
Journal:  Klin Wochenschr       Date:  1987-08-17

8.  Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia.

Authors:  J Cohen; J P Donnelly; A M Worsley; D Catovsky; J M Goldman; D A Galton
Journal:  Lancet       Date:  1983 Dec 24-31       Impact factor: 79.321

9.  Ofloxacin for prevention of bacterial infections in granulocytopenic patients.

Authors:  W Kern; E Kurrle; E Vanek
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

10.  Prevention of bacteremia caused by alpha-hemolytic streptococci by roxithromycin (RU-28 965) in granulocytopenic patients receiving ciprofloxacin.

Authors:  M Rozenberg-Arska; A Dekker; L Verdonck; J Verhoef
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553
View more
  9 in total

1.  Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia.

Authors:  W Kern; E Kurrle
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

2.  Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters.

Authors:  H Syrjälä; P Ohtonen; U Kinnunen; R Räty; E Elonen; T Nousiainen; E Jantunen; K Remes; M Itälä-Remes; R Silvennoinen; P Koistinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-17       Impact factor: 3.267

3.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

5.  Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States.

Authors:  G V Doern; M J Ferraro; A B Brueggemann; K L Ruoff
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

6.  Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin.

Authors:  P H McWhinney; S Patel; R A Whiley; J M Hardie; S H Gillespie; C C Kibbler
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

Review 7.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 8.  Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia.

Authors:  Sarah P Hammond; Lindsey R Baden
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 4.213

9.  Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children.

Authors:  Seung Beom Han; E Young Bae; Jae Wook Lee; Dong-Gun Lee; Nack-Gyun Chung; Dae-Chul Jeong; Bin Cho; Jin Han Kang; Hack-Ki Kim
Journal:  BMC Infect Dis       Date:  2013-06-17       Impact factor: 3.090
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.